申请人:Lilly Industries Limited
公开号:US04675335A1
公开(公告)日:1987-06-23
Pharmaceutical compounds are described of the formula ##STR1## in which R.sup.1 is (i) R.sup.4 O(CH.sub.2 CH.sub.2 O).sub.n (CH.sub.2).sub.m --, where R.sup.4 is hydrogen or C.sub.1-5 alkyl, n is 0 or 1 to 5 and m is 1 to 7, or (ii) R.sup.5 --X-- where R.sup.5 is a polar group and X is a C.sub.6-20 alkylene or a C.sub.6-20 alkenylene radical containing from 1 to 3 double bonds, R.sup.2 is a group of the formula A--B-- where A is --COOH or ##STR2## where R.sup.6 is hydrogen or a protecting group, and B is C.sub.1-6 alkylene, and R.sup.3 is --COOH or ##STR3## where R.sup.7 is hydrogen or a protecting group; or a salt or ester thereof.
该文描述了化合物的公式为##STR1##其中R.sup.1是(i)R.sup.4 O(CH.sub.2 CH.sub.2 O).sub.n(CH.sub.2).sub.m--,其中R.sup.4是氢或C.sub.1-5烷基,n为0或1至5,m为1至7,或(ii)R.sup.5--X--,其中R.sup.5是极性基团,X是C.sub.6-20烷基或含有1至3个双键的C.sub.6-20烯基基团,R.sup.2是公式A--B--的基团,其中A是--COOH或##STR2##其中R.sup.6是氢或保护基团,B是C.sub.1-6烷基,R.sup.3是--COOH或##STR3##其中R.sup.7是氢或保护基团;或其盐或酯。